Full-Time

Clinical Oncology Specialist

Lung Cancer

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Compensation Overview

$195k - $225k/yr

+ Base Salary + Commissions

Senior

Company Historically Provides H1B Sponsorship

Dallas, TX, USA

Frequent travel is required, approximately 75% of the time, including overnight travel as needed.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s degree required
  • 5+ years of experience with consistent success in Hematology/Lung Oncology, Surgical or molecular diagnostics preferred
  • Deep knowledge of academic and community oncology markets, precision medicine, and reimbursement landscape
  • Ability to travel frequently, including overnight travel as needed
  • Valid driver’s license and safe driving record
  • Proven leadership, business acumen, and strong communication skills
  • Travel: ~75% (combination of road and air travel)
Responsibilities
  • Develop and execute a strategic territory plan focused on growth and account penetration
  • Identify and engage KOLs and key accounts to integrate Signatera into clinical decision-making
  • Drive new business development while expanding and deepening existing relationships
  • Maximize return on investment through consistent sales activity and cross-functional collaboration
  • Deliver impactful clinical education to physicians and care teams
  • Serve as a trusted resource in a fast-paced, startup-like environment
  • Build deep understanding of Natera’s oncology solutions, internal processes, and competitor landscape
  • Call on targeted physicians and practices to promote Natera’s oncology products and services
  • Drive product adoption by influencing clinical decision-making at the provider and system level
  • Monitor account performance and market trends; escalate issues and identify new opportunities
  • Consistently conduct business in an ethical, transparent, and professional manner
Desired Qualifications
  • 5+ years of experience with consistent success in Hematology/Lung Oncology, Surgical or molecular diagnostics preferred

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their core technology involves cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services, directly to healthcare providers and patients. The company's goal is to improve patient care through precise genetic insights that enhance treatment outcomes.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Natera's expansion in Austin indicates growth and increased operational capacity by 2026.
  • The launch of the ultra-sensitive Signatera MRD test broadens Natera's clinical offerings.
  • Rising demand for personalized medicine aligns with Natera's mission and service offerings.

What critics are saying

  • Increased competition from companies like Lantheus Holdings may impact market share.
  • Significant capital investments, like the $9.9 million Austin expansion, may affect cash flow.
  • Dependence on insurance reimbursements poses financial risks if policies change.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for oncology, organ health, and women's health.
  • The company offers the Signatera test, a custom-built ctDNA test for cancer patients.
  • Natera provides remote genetic counseling services, enhancing accessibility for patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

5%
Intelligence360
May 15th, 2025
Natera To Spend $9.9 Million To Occupy 30,000 Square Feet Of Space In Austin Texas.

Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas. Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas.Austin, Texas — According to state and local development sources, Natera plans to invest $9,900,000.00 to build out 30,000 square feet of new space in Austin. The company plans to occupy the new space at 13011A McCallen Pass in Austin, on or about January 1, 2026. According to the company website Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, womens health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment

TXBN
Apr 24th, 2025
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera(TM) Genome MRD Test

Natera announces broad clinical launch of ultra-sensitive signatera(tm) genome MRD test.

Slater Sentinel
Apr 3rd, 2025
DnB Asset Management AS Invests $235,000 in Natera, Inc. (NASDAQ:NTRA)

DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).

TXBN
Mar 25th, 2025
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.

Simply Wall St
Mar 13th, 2025
Natera (NasdaqGS:NTRA) Welcomes Former National Cancer Institute Director Back to Board

Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.